{"id":"NCT02791438","sponsor":"Takeda","briefTitle":"A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension","officialTitle":"A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-18","primaryCompletion":"2019-06-04","completion":"2019-06-04","firstPosted":"2016-06-06","resultsPosted":"2019-12-23","lastUpdate":"2020-02-07"},"enrollment":27,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediatric Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan","otherNames":["TAK-536","AZILVA ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Azilsartan 2.5 - 20 mg (Weight < 50 kg)","type":"EXPERIMENTAL"},{"label":"Azilsartan 5 - 40 mg (Weight ≥ 50 kg)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety of administration of azilsartan in pediatric patients aged 6 to less than 16 years with hypertension.","primaryOutcome":{"measure":"Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Up to Week 54","effectByArm":[{"arm":"Azilsartan 2.5 - 20 mg (Weight < 50 kg)","deltaMin":19,"sd":null},{"arm":"Azilsartan 5 - 40 mg (Weight ≥ 50 kg)","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.j-circ.or.jp/english/cj/index.php/jcs-guidelines/"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":22},"commonTop":["Nasopharyngitis","Constipation","Gastroenteritis","Influenza","Abdominal pain"]}}